Micelle-associated protein in epoetin formulations: A risk factor for immunogenicity?

An upsurge of pure red cell aplasia (PRCA) cases associated with subcutaneous treatment with epoetin alpha has been reported. A formulation change introduced in 1998 is suspected to be the reason for the induction of antibodies that also neutralize the native protein. The aim of this study was to de...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical research 2003-12, Vol.20 (12), p.1903-1907
Main Authors: HERMELING, Suzanne, SCHELLEKENS, Huub, CROMMELIN, Daan J. A, JISKOOT, Wim
Format: Article
Language:English
Subjects:
Antibodies
Biological and medical sciences
Chromatography
General pharmacology
Immunoassay
Medical sciences
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Proteins
Risk factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An upsurge of pure red cell aplasia (PRCA) cases associated with subcutaneous treatment with epoetin alpha has been reported. A formulation change introduced in 1998 is suspected to be the reason for the induction of antibodies that also neutralize the native protein. The aim of this study was to detect the mechanism by which the new formulation may induce these antibodies. Formulations of epoetin were subjected to gel permeation chromatography with UV detection, and the fractions were analyzed by an immunoassay for the presence of epoetin. The chromatograms showed that Eprex/Erypo contained micelles of Tween 80. A minute amount of epoetin (0.008-0.033% of the total epoetin content) coeluted with the micelles, as evidenced by ELISA. When 0.03% (w/v) Tween 80, corresponding to the concentration in the formulation, was added to the elution medium, the percentage of epoetin eluting before the main peak was 0.68%. Eprex/Erypo contains micelle-associated epoetin, which may be a risk factor for the development of antibodies against epoetin.
ISSN:0724-8741
1573-904X
DOI:10.1023/B:PHAM.0000008034.61317.02